These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 33807608)

  • 1. Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.
    Ahn R; Ursini-Siegel J
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
    Shin MH; Kim J; Lim SA; Kim J; Lee KM
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turning tumors from cold to inflamed to improve immunotherapy response.
    Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
    Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
    Tolba MF
    Int J Cancer; 2020 Dec; 147(11):2996-3006. PubMed ID: 32415713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunometabolism: A 'Hot' Switch for 'Cold' Pediatric Solid Tumors.
    Xiao L; Yeung H; Haber M; Norris MD; Somers K
    Trends Cancer; 2021 Aug; 7(8):751-777. PubMed ID: 34183305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors.
    Chambers A; Kundranda M; Rao S; Mahmoud F; Niu J
    Curr Oncol Rep; 2021 Jul; 23(9):100. PubMed ID: 34269922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
    Hurkmans DP; Verdegaal EME; Hogan SA; de Wijn R; Hovestad L; van den Heuvel DMA; Ruijtenbeek R; Welters MJP; van Brakel M; Basak EA; Pinedo HM; Lamers CHJ; van de Werken HJG; Groten JP; Debets R; Levesque MP; Dummer R; Kapiteijn E; Mathijssen RHJ; Aerts JGJV; van der Burg SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
    Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
    J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity.
    Donlon NE; Power R; Hayes C; Reynolds JV; Lysaght J
    Cancer Lett; 2021 Apr; 502():84-96. PubMed ID: 33450360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
    Kobayashi Y; Lim SO; Yamaguchi H
    Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
    De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
    Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
    Qu J; Jiang M; Wang L; Zhao D; Qin K; Wang Y; Tao J; Zhang X
    Biomed Pharmacother; 2020 Jul; 127():109996. PubMed ID: 32388240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.